Dynamic Halifax startup
ABK Biomedical
has engaged EnginuityMED to deliver engineering support for their OccluSystem delivery device. ABK are pioneering the use of radio-opaque embolic beads in the targeted treatment of tumors. Following early design in Ireland, ABK have brought core engineering to Halifax, in order to advance the device to production.
“Having access to unique creative engineering on our doorstep is key to meeting our investor expectations and delivering on our key business milestones” says Daniel Boyd, Chief Scientific Officer at ABK, adding “proximity is critical to rapid iteration, that’s what ABK needs as we move to the next phase.”
EnginuityMED are working on refining the device for use in OccluSystem’s preclinical trials, scheduled in early 2015. EnginuityMED will also undertake additional development and OccluSystem refinement for the first round of human testing later in 2015, preparing for a full commercial launch for the product.
EnginuityMED is a collaborative spin off from local mechanical engineering company Enginuity Inc. EnginuityMED successfully launched their FIVA ™ Fluid Intravenous Alerting device into the Canadian market earlier this year.
“We’re working hard to get the relevant regulatory approvals in place for EnginuityMED to provide value to ABK and the many other med tech players blossoming in the Maritimes” adds Ben Garvey, CEO of EnginuityMED Inc, based on Herring Cove Road in Halifax.
Dr Bob Abraham, ABK’s Chief Executive Officer sees the relationship as key to the successful launch of OccluSystem, adding “EnginuityMED have the right mix of skills, concise processes and personality to make the difference moving forwards.”